68 results about "Peripheral neuropathy" patented technology

The present disclosure relates to compositions for increasing acetylated alpha-tubulin levels in peripheral neuronal cells. The present disclosure also relates to the use of tubulin deacetylase inhibitors, or activators of tubulin acetylation for increasing acetylated tubulin levels in the cells. The present disclosure also relates to methods for assessing risk of developing peripheral neuropathy by assessing the levels of acetylated alpha-tubulin. The present disclosure further relates to methods for treating a subject suffering from a peripheral neuropathy using the compositions described herein.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The invention provides a traditional Chinese medicine preparation for treating peripheral neuropathy caused by chemotherapy, the traditional Chinese medicine preparation comprises an external preparation and an internal preparation, and discloses a preparation method and application of the traditional Chinese medicine preparation. The core pathogenesis of qi and blood stasis and yang deficiency and cold coagulation of the peripheral neuropathy caused by chemotherapy and the characteristic treatment method of tonifying qi and activating blood and warming yang and dredging collaterals are innovatively provided; the composition is rigorous and rigorous, and is clinically safe and effective.

The invention discloses an application of fenoterol hydrobromide and pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic peripheral neuropathy. The fenoterol hydrobromide and the pharmaceutically acceptable salt thereof have obvious effects of promoting growth of peripheral sensory neurite and protecting myelin sheath injury, and can improve symptoms of slow nerve conduction speed and sensory deficiency induced by diabetes mellitus.

The invention belongs to the technical field of medical apparatus and instruments, and discloses a household traditional Chinese medicine directional drug permeation device applied to chemotherapy-related peripheral neuropathy, the household traditional Chinese medicine directional drug permeation device comprises an adjustable electrode plate and an elastic bandage, the adjustable electrode plate comprises a main electrode plate and a branch electrode plate detachably mounted at any side position of the main electrode plate; the whole main electrode plate is of an E-shaped structure; square medicine cores are respectively arranged in the three-finger section of the main electrode plate and the rectangular grooves in the bottoms of the branch electrode plates; and elastic bandages cover the front and rear ends of the tops of the main electrode plate and the branch electrode plates. Through improvement and innovation of the shape of the electrode slice, the electrode slice is designed to be of an integrated structure according to the position relation of the eight-wind-eight-evil acupuncture points, the electrode slice is applied to drug penetration treatment of the eight-wind-eight-evil acupuncture points at the tail ends of the four limbs, a personalized treatment scheme can be provided according to the specific conditions of a patient, the treatment accuracy and effectiveness are enhanced, and the treatment cost is reduced. And a new normal form for treating the chemotherapy-related peripheral neuropathy is created.

The invention discloses a traditional Chinese medicine composition for treating diabetic peripheral neuropathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 10-20 parts of angelica sinensis, 8-15 parts of cassia twig, 8-15 parts of red paeony root, 15-30 parts of caulis spatholobi, 5-10 parts of tetrapanax papyriferus, 3-6 parts of scorpio and 1-3 parts of centipede.

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention provides a pharmaceutical composition for treating an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition comprising an alkalizing agent. By administering this pharmaceutical composition, it is possible to treat an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, in particular, a chemotherapeutic agent for cancer. The present invention also provides an anticancer pharmaceutical composition that contains an alkalizing agent and a chemotherapeutic agent for cancer and that is designed to suppress an acute-phase peripheral neuropathy induced by the chemotherapeutic agent or to suppress worsening of symptoms caused by the peripheral neuropathy. By administering this pharmaceutical composition, it is possible to provide a cancer treatment in which an acute-phase peripheral neuropathy or worsening of symptoms caused by the peripheral neuropathy is suppressed.

The present invention relates to a multilayer pharmaceutical or nutraceutical solid dosage form comprising at least one pyrimidine derivative, purine derivative or any salt or solvate thereof and least one B-group vitamin. It also provides three methods for producing said multilayer pharmaceutical or nutraceutical solid dosage forms. Furthermore, the present invention is also related to therapeutic uses of said multilayer pharmaceutical or nutraceutical solid dosage forms, particularly for the treatment and / or prevention of peripheral neuropathy.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

The invention provides application of ursodesoxycholic acid in preparation of a medicine for treating peripheral neuropathy. The ursodesoxycholic acid provided by the invention can promote the recovery of sciatic nerve function indexes after the sciatic nerve of a mouse is cut off, and improve the electroneurographic signal conduction function of an injured part; meanwhile, the UDCA can also relieve oxaliplatin-induced ischiadic nerve signal transduction disorder of mice and related crymodynia sensitive symptoms. In addition, the invention further reveals that the relieving effect of the UDCA on the peripheral neuropathy does not depend on promoting Schwann cell migration. According to the discovery, the application value of the UDCA in treating peripheral neuropathy caused by multiple factors is expanded, and a new strategy is provided for clinical treatment of the UDCA.

The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and / or using the antibodies and / or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.

To provide a method for ameliorating adverse event peripheral neuropathies in a subject undergoing treatment with an anti- CD30 antibody-drug conjugate and optionally also receiving concomitant chemotherapies.SOLUTION: 1. Provided is a method of treating a subject who has exhibited peripheral neuropathy of Grade 2 or greater after initiating treatment with an anti- 2mg antibody-drug conjugate therapy at a dose of CD30 / kg or greater, comprising administering the anti- 9mg antibody-drug conjugate therapy at a dose of 0. CD30 / kg.SELECTED DRAWING: None

The application relates to the technical field of compound medicines, and discloses application of a compound external-use patch for preventing and treating diabetic peripheral neuropathy, wherein the compound external-use patch comprises a gel base and dry extract and volatile oil doped into the gel base, the dry extract and the volatile oil are derived from a compound, and the compound is composed of 10-20 parts of cinnamon, 8-12 parts of asarum, 8-12 parts of evodia, 8-12 parts of chuanxiong and 0.2-0.8 parts of borneol in terms of weight parts. The compound external-use patch of the application is locally pasted on acupoints or joints of DPN rats, can reduce the blood sugar level of diabetic peripheral neuropathy rats, increase the insulin level, improve insulin resistance, prolong the latent period of hot stimulation foot withdrawal, increase the nerve conduction velocity, maintain the normal morphology and function of nerve cells, and therefore can prevent and inhibit the generation and deterioration of diabetic peripheral neuropathy; and the compound external-use patch improves the safety and convenience of patients in taking medicine compared with oral medicine.

The application discloses application of a glucose transporter 1 inhibitor in preparation of a drug for treating diabetic neuropathy. The application verifies that the glucose transporter 1 inhibitor BAY-876 can be used as a drug for treating diabetic peripheral neuropathy and can be combined with mecobalamin to be used as a drug for treating diabetic peripheral neuropathy through pharmacodynamics experiments.

Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.

The invention discloses a method for researching the action mechanism of saikoside D on paclitaxel-induced peripheral neuropathy, and relates to the technical field of disease mechanism research and drug development. Comprising the following steps: performing continuous administration through intraperitoneal injection of paclitaxel, and establishing a paclitaxel-induced peripheral neuropathy animal model; a von Frey cellosilk experiment and a cold and hot plate experiment are adopted for behavioral detection, and mechanical pain threshold and cold and hot pain sense changes are evaluated; the morphological structure change of the sciatic nerve myelin sheath is observed through Luxol Fast Blue staining; and the expression level of the myelin sheath basic protein in the sciatic nerve is detected by using immunofluorescence staining and Western blotting technologies. According to the invention, a closed-loop research system is formed from animal model construction to molecular mechanism verification; based on behavioral detection, histological analysis and multiple dimensions of a molecular biological technology, the data reliability is ensured, and the curative effect of saikoside D can be comprehensively evaluated.

The invention provides an application of a nitrogen-containing heterocyclic ring compound in preparation of a medicine for treating peripheral neuropathy. The nitrogen-containing heterocyclic ring compound is SB203580. The peripheral neuropathy refers to diseases or injuries involving a peripheral nervous system, and comprises peripheral nerve trauma, adverse drug reaction and axonal dysfunction caused by one or more pathogenic factors of chemical reagents and diabetes mellitus. Researches show that recovery of a sciatic nerve function index (SFI) after peripheral nerve physical injury (sciatic nerve truncation) of a mouse is remarkably improved, the recovery degree of the signal transduction rate of the injured sciatic nerve is improved, myelin sheath regeneration of the injured sciatic nerve is promoted, and the proportion of abductive myelin sheaths in newly formed myelin sheaths is reduced. The invention provides a new potential medicine for treating the peripheral nerve injury. The structure of the SB203580 is shown in the specification.

The application provides use of rhodioloside in preparation of a medicine for preventing and / or treating paclitaxel-induced peripheral neuropathy, and belongs to the technical field of biological medicine. The application provides systematic pharmacodynamic evidence and molecular mechanism interpretation for prevention and treatment of paclitaxel-related peripheral neuropathy, and is expected to be developed into a new candidate medicine for preventing and / or treating paclitaxel-induced peripheral neuropathy, and has good clinical transformation prospect.

This disclosure relates to the use of Purine Nucleoside Phosphorylase (PNP) inhibitors such as ulodesine and its salts, in the treatment and / or prevention of diseases associated with nicotinamide adenine dinucleotide (NAD+) depletion, including diseases of mitochondrial dysfunction (including neurodegeneration and peripheral neuropathies), the preservation of cognitive function and in muscular disorders such as sarcopenia; and in metabolic syndrome and associated conditions. In particular the disclosure provides the use of PNP inhibitors such as ulodesine in the treatment of neurodegenerative conditions such as Parkinson's disease and amyotrophic lateral sclerosis.

The invention discloses a supporting device for treating foot peripheral neuropathy of diabetes mellitus, and belongs to the technical field of medical instruments, the supporting device comprises a frame, a supporting mechanism, a temperature adjusting system and a displacement mechanism, two movable frames are arranged in the middle of the frame, and the movable frames can move in the horizontal or vertical direction through the displacement mechanism; the supporting mechanism and the temperature adjusting system are arranged on the movable frame, the temperature adjusting system can provide warm air or natural air for the interior of the supporting mechanism, and the temperature adjusting system can be manually controlled or automatically controlled according to actual conditions. The response mechanism can automatically judge whether a user exists or not through a pressure sensor, the fan can be automatically controlled to adjust the leg temperature according to the deformation characteristics of the memory metal wire at different temperatures, the relative position of the supporting mechanism can be flexibly adjusted through the displacement mechanism, the use requirements under different working conditions are met, and the practicability is high. The problems that in the prior art, the leg temperature cannot be automatically adjusted, and the position of a supporting device is fixed and inflexible are solved.

The present invention relates to the use of botulinum toxins for the treatment of peripheral neuropathic pain (PNP) by topical administration of botulinum toxins. The administration includes subcutaneously injecting an effective amount of botulinum toxin into a region of the skin of the patient affected by pain according to a specific administration regimen. The peripheral neuropathic pain may be, for example, post-herpes zoster neuralgia, peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain), and painful nerve root disease.

The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.

The invention relates to the technical field of medical instruments, and particularly discloses a constant-pressure traditional Chinese medicine foot recuperating instrument for diabetic peripheral neuropathy. The device comprises a control box, a medicine storage tank and a hard foot sleeve body. By arranging a closed-loop control system composed of a pressure sensor, a micro air pump and a main controller, the pressure of liquid medicine in the flexible inner container is monitored in real time and dynamically adjusted, and it is ensured that constant seepage pressure is maintained. A peristaltic pump is adopted to drive liquid medicine to circulate, and continuous and stable medicine permeation is achieved in cooperation with a medical silica gel porous membrane. The device is further provided with a heating module and a temperature sensor, and the temperature of the liquid medicine is accurately controlled within a safe range. A unique negative pressure recovery system can completely recover residual liquid medicine after treatment is finished, and waste is avoided. The buffer device can effectively absorb impact force generated by the foot. The problem that traditional pedicure equipment is low in medicine permeation efficiency due to unstable pressure is solved, and a safe and efficient household recuperating solution is provided for diabetic foot patients.

The inventors' primary objective was to provide a new technology for preventing and / or improving peripheral neuropathy. [Solution] The present inventors have found that peripheral neuropathy may be prevented and / or ameliorated by nafamostat or a pharmaceutically acceptable salt thereof, or a solvate thereof.

To provide a compound for treating neurodegenerative disorders such as diabetic peripheral neuropathy.SOLUTION: Characterized by an X-ray powder diffractogram comprising the following peaks: 14.76, 16.86, 19.00 and 21.05 ° 2 θ ± 0.20 ° 2 θ, as determined on a diffractometer with Cu-K α radiation at a wavelength of 1.54178 Å. A cocrystal of N - (2 - (5 - (((2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-methoxy-6, 6-dimethyltetra-hydro -2H - pyran-2-yl) oxy) -3' - fiuoro - [l, l' - biphenyl] -2-yl) ethyl) - acetamide and L-proline (1:2).SELECTED DRAWING: None

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

Provided is a pharmaceutical composition for treating or preventing peripheral neuropathy induced by a chemotherapy drug, the pharmaceutical composition containing an alkalinizing agent. Administration of this pharmaceutical composition enables the treatment or prevention of peripheral neuropathy induced by a chemotherapy drug, particularly a cancer chemotherapy drug. Also provided is an anticancer pharmaceutical composition which contains an alkalinizing agent and a cancer chemotherapy drug, and exhibits suppressed expression of peripheral neuropathy. Administration of this pharmaceutical composition enables cancer treatment with suppressed expression of peripheral neuropathy.